Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).

e16017 Background: After DOC became the reference first line treatment for mCRPC pts, cabazitaxel (CABA), abiraterone acetate (AA), and enzalutamide (ENZ) significantly prolonged overall survival (OS) after DOC. Since a quote of pts develops mCRPC at very old age, often after 80 years, it could be questionable if the administration of these expensive NAs is justifiable in this population. We retrospectively evaluated the impact of post-DOC treatments on OS of octogenarians mCRPC pts treated with first-line DOC in 30 Italian hospitals. Methods: In this multicentric retrospective study, after Ethical Committee approval, we have reviewed the clinical records of all octogenarians mCRPC pts from participating institutions, treated with DOC in clinical practice, recording the pre and post-DOC clinical history, the DOC treatment details and outcomes. Results: We collected a consecutive series of 121 octogenarians pts treated between May 2003 and November 2013. The median age was 82 yrs (range 80-90). All pts had...